Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Mylan Inc

Article Abstract:

The price appreciation potential of the shares of Mylan Inc. for the years 2010-2012 is discussed. The Pittsburgh, Pennsylvania-based company offers prescription generic drugs such as antibiotics and anti-inflammatory agents and brand-name dermatological products.

Author: Butler, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
United States, Pharmaceutical preparations, Pharmaceutical industry, Mylan Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Biogen Idec

Article Abstract:

The price appreciation potential of the shares of Biogen Idec for the years 2010-2012 is discussed. The San Diego, California-based company develops products for the long-term management of cancers, auto-immune, and inflammatory diseases.

Author: Bulter, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2008
Commercial physical research, Biological products exc. diagnostic, Biotechnology industry, Biotechnology industries, Biogen Idec, Analyst report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: United States, Evaluation, Stocks, Securities, Stock prices, Company securities
Similar abstracts:
  • Abstracts: Biogen Idec. Human Genome Sci
  • Abstracts: Kinder Morgan En
  • Abstracts: Synchronoss Tech. DivX, Inc. Flowers Foods
  • Abstracts: Quicksilver Res. Altria Group, Inc
  • Abstracts: Potash Corp. Vail Resorts Inc. Int'l Speedway
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.